A067080 Stock Overview
A pharmaceutical company, produces and supplies pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
DAE HWA Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,150.00 |
| 52 Week High | ₩24,150.00 |
| 52 Week Low | ₩8,290.00 |
| Beta | 0 |
| 11 Month Change | -30.05% |
| 3 Month Change | 29.17% |
| 1 Year Change | 46.60% |
| 33 Year Change | 46.93% |
| 5 Year Change | 13.36% |
| Change since IPO | 413.67% |
Recent News & Updates
Shareholder Returns
| A067080 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.8% | -3.1% | 2.9% |
| 1Y | 46.6% | 4.8% | -2.8% |
Return vs Industry: A067080 exceeded the KR Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: A067080 exceeded the KR Market which returned -2.8% over the past year.
Price Volatility
| A067080 volatility | |
|---|---|
| A067080 Average Weekly Movement | 16.2% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A067080's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A067080's weekly volatility has increased from 10% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Kim Eun-Seok | www.dhpharm.co.kr |
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, urinary incontinence, prostatic hyperplasia, pregnancy, bug bite, anthelmintics, and cosmetic care, as well as vitamins and minerals, tonics, nutrition products. It also provides transdermal drug delivery system, a pharmaceutical preparation that is applied to the intact skin for systemic absorption; and active pharmaceutical ingredients.
DAE HWA Pharmaceutical Co., Ltd. Fundamentals Summary
| A067080 fundamental statistics | |
|---|---|
| Market cap | ₩216.33b |
| Earnings (TTM) | ₩10.76b |
| Revenue (TTM) | ₩115.31b |
0.0x
P/E Ratio0.0x
P/S RatioIs A067080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A067080 income statement (TTM) | |
|---|---|
| Revenue | ₩115.31b |
| Cost of Revenue | ₩66.94b |
| Gross Profit | ₩48.36b |
| Other Expenses | ₩37.60b |
| Earnings | ₩10.76b |
Last Reported Earnings
Mar 31, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A067080 perform over the long term?
See historical performance and comparison